JP5205276B2 - 酵素阻害剤 - Google Patents

酵素阻害剤 Download PDF

Info

Publication number
JP5205276B2
JP5205276B2 JP2008546614A JP2008546614A JP5205276B2 JP 5205276 B2 JP5205276 B2 JP 5205276B2 JP 2008546614 A JP2008546614 A JP 2008546614A JP 2008546614 A JP2008546614 A JP 2008546614A JP 5205276 B2 JP5205276 B2 JP 5205276B2
Authority
JP
Japan
Prior art keywords
mmol
pyridine
piperazine
imidazo
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008546614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009520791A (ja
JP2009520791A5 (enExample
Inventor
バヴェトシアス，ヴァッシリオス
マクドナルド，エドワード
リナードプロス，スピリドン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Cancer Research Royal Cancer Hospital
Original Assignee
Institute of Cancer Research Royal Cancer Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0526169A external-priority patent/GB0526169D0/en
Priority claimed from GB0620884A external-priority patent/GB0620884D0/en
Application filed by Institute of Cancer Research Royal Cancer Hospital filed Critical Institute of Cancer Research Royal Cancer Hospital
Publication of JP2009520791A publication Critical patent/JP2009520791A/ja
Publication of JP2009520791A5 publication Critical patent/JP2009520791A5/ja
Application granted granted Critical
Publication of JP5205276B2 publication Critical patent/JP5205276B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2008546614A 2005-12-22 2006-12-21 酵素阻害剤 Active JP5205276B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0526169.8 2005-12-22
GB0526169A GB0526169D0 (en) 2005-12-22 2005-12-22 Enzyme inhibitors
GB0620884A GB0620884D0 (en) 2006-10-20 2006-10-20 Enzyme inhibitors
GB0620884.7 2006-10-20
PCT/GB2006/004854 WO2007072017A2 (en) 2005-12-22 2006-12-21 Enzyme inhibitors

Publications (3)

Publication Number Publication Date
JP2009520791A JP2009520791A (ja) 2009-05-28
JP2009520791A5 JP2009520791A5 (enExample) 2010-02-12
JP5205276B2 true JP5205276B2 (ja) 2013-06-05

Family

ID=38091678

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008546614A Active JP5205276B2 (ja) 2005-12-22 2006-12-21 酵素阻害剤

Country Status (5)

Country Link
US (1) US8088761B2 (enExample)
EP (1) EP1963315B1 (enExample)
JP (1) JP5205276B2 (enExample)
ES (1) ES2526813T3 (enExample)
WO (1) WO2007072017A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008121064A1 (en) * 2007-03-30 2008-10-09 Astrazeneca Ab New imidazo[4,5-b]pyridine-6-halo-7-aryl/heteroaryl compounds 705
WO2009001021A1 (en) * 2007-06-26 2008-12-31 Chroma Therapeutics Ltd. Imidazopyridine derivatives useful as enzyme inhibitors for the treatment of cell proliferative and autoimmune diseases
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
WO2013116291A1 (en) * 2012-01-30 2013-08-08 Cephalon, Inc. Imidazo [4, 5 - b] pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders
SG11201406818VA (en) 2012-04-23 2014-11-27 Genentech Inc Intermediates and processes for preparing compounds
GB201211021D0 (en) * 2012-06-21 2012-08-01 Cancer Rec Tech Ltd Pharmaceutically active compounds
GB201211019D0 (en) * 2012-06-21 2012-08-01 Cancer Rec Tech Ltd Inhibitor compounds
ES2620119T3 (es) 2012-11-16 2017-06-27 Merck Patent Gmbh Derivados heterocíclicos novedosos como moduladores de la actividad de quinasa
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
WO2016073738A2 (en) 2014-11-05 2016-05-12 Flexus Biosciences, Inc. Immunoregulatory agents
EP3253754B1 (en) 2015-02-02 2021-03-31 Kancera AB 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity
US11660303B2 (en) 2016-07-11 2023-05-30 Kancera Ab 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
ES2899113T3 (es) 2016-07-11 2022-03-10 Kancera Ab Derivados de 2-fenilimidazo[4,5-b]piridin-7-amina útiles como inhibidores de la actividad tirosina quinasa ROR1 de mamíferos
CN112239465A (zh) 2019-07-16 2021-01-19 微境生物医药科技(上海)有限公司 极光激酶抑制剂及其用途
WO2024017977A1 (en) * 2022-07-20 2024-01-25 Sanofi Imidazopyridine compounds, preparation thereof and therapeutic uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID24300A (id) * 1997-08-05 2000-07-13 Pfizer Prod Inc 4-AMINOPIROL(3,2-d)PIRIMIDIN SEBAGAI ANTAGONIS-ANTAGONIS RESEPTOR NEUROPEPTIDA Y
US6943174B2 (en) 2000-06-14 2005-09-13 Warner-Lambert Company 6,5-Fused bicyclic heterocycles
SE0202462D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel use
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor

Also Published As

Publication number Publication date
WO2007072017A2 (en) 2007-06-28
ES2526813T3 (es) 2015-01-15
WO2007072017A3 (en) 2007-08-16
EP1963315B1 (en) 2014-10-08
EP1963315A2 (en) 2008-09-03
US8088761B2 (en) 2012-01-03
US20090247507A1 (en) 2009-10-01
JP2009520791A (ja) 2009-05-28

Similar Documents

Publication Publication Date Title
US11773110B2 (en) Heterocycle amines and uses thereof
JP4471665B2 (ja) ヒストンデアセチラーゼ阻害剤として有用なベンズアミド誘導体
US20040106574A1 (en) 2-Arylamino-pyrimidines for the treatment of gsk3-related disorders
US7547779B2 (en) Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors
JP5205276B2 (ja) 酵素阻害剤
JP2014510154A (ja) 神経変性疾患の治療方法及び治療用組成物
JP2019519534A (ja) 五員複素環［３，４−ｄ］ピリダジノン系化合物、その製造方法、医薬組成物及び応用
JP2025522274A (ja) Ｐａｒｇの阻害剤
AU2012233246A1 (en) Novel furanone derivative
JP7763538B2 (ja) Ｐａｒｐ７阻害剤及びその使用
US20080255106A1 (en) Novel 2-Phenyl-Imidazo[4,5-B]Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase for the Treatment of Dementia and Neurodegenerative Disorders
CA3181351A1 (en) Nampt modulators
HK40083035B (zh) Parp7抑制剂及其用途
WO2022028556A1 (zh) Cdk9抑制剂及其用途
HK1197677B (en) Heterocycle amines and uses thereof
AU2002232346A1 (en) 2-arylamino-pyrimidines for the treatment of GSK3-related disorders
HK1197677A (en) Heterocycle amines and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120724

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121016

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130218

R150 Certificate of patent or registration of utility model

Ref document number: 5205276

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160222

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250